Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status approved; investigational
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 0781-9253; 14096-121; 81955-0012; 16729-306; 55150-393; 63323-771; 68001-527; 69097-368; 69097-805; 71288-153; 72485-201; 65129-1222; 68554-0104; 72606-558; 53183-4011; 43598-678; 59572-102; 51916-350; 83137-0006; 16714-927; 43817-906; 59572-730; 68001-504; 71288-115; 63660-0010; 0781-3253; 42385-312; 66529-0013; 54893-0029; 82920-015; 68001-313; 42385-719; 43598-305; 16714-578; 51991-797; 64679-096; 70121-1237; 63592-1800; 0143-9606; 43598-143; 43598-465; 59572-740
UNII M801H13NRU
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pleural effusion22.05.02.0020.002574%
Pleurisy22.05.01.0010.000168%Not Available
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumonia klebsiella22.07.06.001; 11.02.03.001--Not Available
Pneumonitis22.01.01.0060.000862%
Pneumothorax22.05.02.003--
Polycythaemia01.07.01.0010.000168%Not Available
Polyneuropathy17.09.03.0120.000112%Not Available
Polyuria20.02.03.0020.000224%Not Available
Portal vein thrombosis09.01.06.007; 24.01.03.0030.000112%
Proctalgia07.03.02.0010.000224%
Productive cough22.02.03.005--
Prostatic disorder21.04.01.0010.000112%Not Available
Prostatitis21.09.01.0010.000280%Not Available
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.001--
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.000392%Not Available
Pulmonary haemorrhage24.07.01.016; 22.12.01.0090.000336%
Pulmonary oedema22.01.03.003; 02.05.02.0030.000616%
Purpura24.07.06.005; 23.06.01.004; 01.01.04.0030.000168%
Pyoderma gangrenosum10.04.02.009; 23.07.03.001; 16.32.03.0050.000895%Not Available
Pyogenic granuloma24.03.06.002; 23.10.01.001; 16.26.01.001; 07.20.02.0040.000112%Not Available
Pyrexia08.05.02.0030.011103%
Rales22.12.01.011--Not Available
Rash23.03.13.001--Not Available
Rash macular23.03.13.0030.000224%Not Available
Rash pruritic23.03.13.030--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.000616%
Renal disorder20.01.02.0020.001198%Not Available
Renal failure20.01.03.0050.002966%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 19 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene